Obsidian Therapeutics, Inc. (OBX)

Price$17.04Cached quoteAs of 2026-09-04 16:23 UTC

AI: Fair-priced

Price checkThe market price looks fair because investors are paying heavily for clinical success, not current earnings.

With 61.77 million shares outstanding, the observed price implies a stock-market value near $1.07 billion. Management reported about $350 million of post-transaction cash, cash equivalents and investments, leaving roughly $716 million of value assigned to the drug programs and platform before lease obligations. The stock also sits roughly 44% above the financing investors’ effective entry price. That premium is plausible after encouraging melanoma data, but there are no approved products or durable earnings, so the balance of upside and clinical risk looks fair rather than clearly cheap.

Big pictureCash runway is solid for now, but ongoing losses make future financing a real part of the story.

The supplied history shows cash and equivalents falling from $40.4 million at year-end 2025 to $18.0 million by Q2 2026, with $46.4 million of current assets against $20.2 million of current liabilities before the deal financing. SEC filings show Legacy Obsidian lost $45.5 million and used $47.3 million of operating cash in the first half of 2026. The $350 million financing reset liquidity; its investors own about 47.2% of the post-deal company. Management expects runway into the second half of 2028, but another capital raise may still be needed before commercialization.

Business strengthPromising melanoma responses are the core strength, but the evidence remains small and concentrated in one lead drug.

Amsoki-cel produced a 67% objective response rate at the recommended Phase 2 dose in 15 patients, including 2 complete responses, with no reported treatment-related deaths, intensive-care transfers, major neurotoxicity or dose-limiting toxicities. FDA discussions supported starting a single-arm registration-enabling cohort, which could shorten the path if results hold. The bear case is concentration: the company has no approved product or recurring product revenue, and a small trial can overstate durability. This is not ordinary economic cyclicality; value will swing mainly with clinical and regulatory milestones.

What could change the storyLarger melanoma data and 2027 lung-cancer results will decide whether today’s valuation is justified.

The clearest upside trigger is the registration-enabling melanoma cohort maintaining something near the earlier response rate with durable responses and acceptable safety as enrollment scales; topline data are expected by year-end 2027. Phase 1 non-small cell lung cancer data are expected in the first half of 2027 and could broaden the opportunity. A weaker response rate, safety problems, enrollment delays or a longer approval path would reduce the roughly $716 million value now placed above cash. Strong results could support a future approval filing and materially raise that implied drug-program value.

AI: News

Merger and financing closedThe merger closed with major new funding, giving Obsidian a public listing and a much longer cash runway.

On August 3, Obsidian completed its transaction with Galera and the previously announced $350 million private financing. Former Obsidian holders owned about 51.6% of the combined company, financing investors about 47.2%, and former Galera holders about 1.2%. Shares began Nasdaq trading the next day, and the first OBX session closed about 79% above the prior reference close. That move cannot be cleanly attributed to the closing alone because it was also the stock’s debut after a reverse split and merger, with very low early volume.

Registration cohort startedThe first registration-enabling melanoma patient was enrolled after FDA alignment on a single-arm accelerated-approval strategy.

On August 5, Obsidian said the first patient entered the registration-enabling amsoki-cel cohort and that FDA discussions supported the single-arm design. The earlier recommended-dose cohort showed a 67% response rate in 15 patients, including 2 complete responses, with topline registration data targeted for year-end 2027. Shares closed about 16% lower that day, but attribution is uncertain because OBX had only just started trading and remained unusually volatile, so the move cannot be treated as a clean verdict on the clinical update.

Large resale registrationA large resale registration increased potential share supply even though the company received no new cash from it.

The late-August S-1 registered up to 29.16 million shares for resale by financing investors, equal to roughly 47% of the 61.77 million shares outstanding after the merger. Obsidian receives no proceeds when those holders sell. The filing does not mean all shares will be sold, and it does not prove any particular price decline was caused by the registration, but it materially increases the amount of stock that can reach the market and can weigh on near-term trading.

Loading local price history

Revenue

2024

2025

Net income

2024

2025

Free cash flow

2024

2025

Total cash / debt

CashTotal debt

2024

2025

Financial statements

	2025	2024
Revenue	$1,986	$31
Research & development	$17.1	$13.3
Operating expenses	$105.7M	$91.3M
Operating income	−$105.7M	−$91.3M
Operating margin	−5,320,594.16%	−294,370,967.74%
EBITDA	−$104.2M	−$89.7M
EBITDA margin	−5,245,871.10%	−289,445,161.29%
Net income	−$100.6M	−$83.1M
Net profit margin	−5,065,810.67%	−268,093,548.39%
Basic EPSper basic share	-$1.63	-$1.35
Diluted EPSper diluted share	-$1.63	-$1.35